Opinion

Video

Positioning PDS Within the Therapeutic Landscape

Dr. Dennis Marcus discusses how the PDS with ranibizumab fits into the treatment landscape and explores other sustained delivery mechanisms currently in development for neovascular AMD.

Video content above is prompted by the following:

  • How does the PDS with ranibizumab fit into the treatment landscape that also includes highly durable agents such as faricimab and high-dose aflibercept?
  • What other sustained delivery mechanisms are currently in development for neovascular AMD?
Related Videos
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Eric W Schneider, MD: Comparing AI-Based Home OCT to In-Office OCT Scans | Image Credit: Tennessee Retina
Wendy Wright, DNP, an expert on fibromyalgia
Wendy Wright, DNP, an expert on fibromyalgia
Wendy Wright, DNP, an expert on fibromyalgia
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this Insights series.
© 2024 MJH Life Sciences

All rights reserved.